VISION Vaccine Effectiveness Network

What to know

Established in 2019, the Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION) is a research collaboration between CDC, Westat, and multiple health systems in the United States with integrated medical, laboratory, pharmacy, billing, and vaccination records and linkages to state and local immunization information systems. The network evaluates how well vaccines and preventive products (e.g., monoclonal antibodies) work to protect people from illness and complications caused by infection with respiratory syncytial virus (RSV), SARS-CoV-2, and seasonal influenza viruses.

Background

VISION's primary objective is to assess COVID-19, influenza, and RSV vaccine and product effectiveness across age groups, care settings, disease severity, and population subgroups (e.g., people with immunocompromising conditions). VISION also assesses information on severe outcomes among people hospitalized with laboratory-confirmed flu and COVID-19, including intensive care unit (ICU) admission, invasive mechanical ventilation, and in-hospital death. These data help inform how well flu vaccines and COVID-19 vaccines protect against severe outcomes.

Secondary objectives include:

1) Assessing COVID-19, influenza, and RSV testing frequency, test type, and test results across age groups, care settings, disease severity, and population subgroups;

2) Assessing COVID-19, influenza, and RSV vaccination uptake by dose number and product type among people hospitalized with acute respiratory infection;

3) Describing the epidemiology and clinical characteristics of COVID-19, influenza, and RSV across age groups, care settings, disease severity, and population subgroups;

4) Describing the trajectory of care for individuals with COVID-19, influenza, and RSV, including severe outcomes (e.g., ICU admission, mechanical ventilation, in-hospital death) and post-acute sequelae (e.g., new-onset clinical diagnoses);

5) Assessing use of therapies for the treatment and prophylaxis of respiratory viruses and evaluating the ability of these therapies to prevent illness and/or reduce disease severity.

Sites and Study Design

VISION is composed of 9 participating sites in 11 different states:

VISION uses a test-negative case-control design as well as a prospective cohort design with data collected by participating sites.

Graph illustrating VISION site participation
Vision site participation
Map of vision sites across the country
Map of VISION sites across the country

VISION Publications

2024

  • Link-Gelles R, Rowley EAK, DeSilva M.B. et al Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR. Morbidity and mortality weekly report 2024; 73(12), 271–276. https://doi.org/10.15585/mmwr.mm7312a5
  • Levy ME, Yang D, Dunne MM, et al. Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders. Influenza and Other Respiratory Viruses. 2024;18(3). doi:https://doi.org/10.1111/irv.13269
  • DeCuir J, Payne AB, Self WH, et al. Interim effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged ≥18 years - VISION and IVY Networks, September 2023-January 2024. MMWR. Morbidity and Mortality Weekly Report. 2024;73(8):256-262. https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a5.htm
  • Frutos AM, Price AM, Harker E, et al. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity and Mortality Weekly Report. 2024;73. doi:https://doi.org/10.15585/mmwr.mm7308a3

2023

  • Adams K, Weber ZA, Yang DH, et al. Vaccine Effectiveness Against Pediatric Influenza-A–Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022–2023 Season: VISION Network. Clinical Infectious Diseases. 2023;78(3):746-755. doi:https://doi.org/10.1093/cid/ciad704
  • DeSilva MB, Knowlton G, Rai, NK. et al. Vaccine effectiveness against SARS-CoV-2 related hospitalizations in people who had experienced homelessness or incarceration - Findings from the Minnesota EHR Consortium. Journal of Community Health. 2023;48(4):610-617. https://link.springer.com/article/10.1007/s10900-023-01308-3
  • Patel P, Schrader KE, Rice CE, et al. Effectiveness of the original monovalent coronavirus disease 2019 vaccines in preventing emergency department or urgent care encounters and hospitalizations among adults with disabilities: VISION Network, June 2021-September 2022. Open Forum Infectious Diseases. 2023;10(11) https://academic.oup.com/ofid/article/10/11/ofad474/7286130
  • Griggs EP, Mitchell PK, Lazariu V, et al. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 States, June 2021-March 2023. Clinical Infectious Diseases. 2023;78(2):338-347. https://academic.oup.com/cid/article/78/2/338/7252326
  • Link-Gelles R, Ciesla AA, Rowley EA, et al. Effectiveness of monovalent and bivalent mRNA vaccines in preventing COVID-19-associated emergency department and urgent care encounters among children aged 6 months-5 years - VISION Network, United States, July 2022-June 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72(33):998-1003. https://www.cdc.gov/mmwr/volumes/72/wr/mm7233a2.htm
  • Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. JAMA Network Open. 2023;6(6) https://doi.org/10.1001/jamanetworkopen.2023.2598
  • Bozio CH, Butterfield KA, Briggs Hagen M et al. Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. Journal of Infectious Diseases. 2023;227(12):1348-1357. https://academic.oup.com/jid/article/227/12/1348/7045997
  • Embi PJ, Levy ME, Patel P, et al. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023;41(22):3411-3418. https://doi.org/10.1016/j.vaccine.2023.05.038
  • Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72(21):545-550. https://www.cdc.gov/mmwr/volumes/72/wr/mm7221a3.htm?s_cid=mm7221a3_w
  • Adams K, Riddles JJ, Rowley EAK, et al. Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study. The Lancet. 2023;5(3) https://doi.org/10.1016/j.lana.2023.100530
  • Dalton AF, Weber ZA, Allen KS, et al. Relationships between social vulnerability and COVID-19 vaccination coverage and vaccine effectiveness. Clinical Infectious Diseases. 2023;76(9): 1615-1625 https://doi.org/10.1093/cid/ciad003
  • Tenforde MW, Weber ZA, DeSilva MB, et al. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021–2022 Season, VISION Network. The journal of infectious diseases (Online University of Chicago Press)/The Journal of infectious diseases. 2023;228(2):185-195. doi:https://doi.org/10.1093/infdis/jiad015
  • Tenforde MW, Weber ZA, Yang DH, et al. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023, The Journal of Infectious Diseases, Volume 230, Issue 1, 15 July 2024, Pages 141–151, https://doi.org/10.1093/infdis/jiad542
  • Rao S, Bozio C, Butterfield K, et al. Accuracy of COVID-19-Like-Illness Diagnoses in Electronic Health Record Data: Retrospective Cohort Study (Preprint). JMIR Formative Research. Published online May 3, 2022;7:e39231 doi:https://doi.org/10.2196/39231

2022

  • Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults — VISION Network, nine states, September–November 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(51-52):1653-1658. https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e1.htm
  • Ferdinands J M, Rao S, Dixon B E, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379 https://www.bmj.com/content/379/bmj-2022-072141
  • Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance — VISION Network, 10 states, December 2021— August 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(42):1328-1333. https://www.cdc.gov/mmwr/volumes/71/wr/mm7142a4.htm?s_cid=mm7142a4_w
  • DeSilva MB, Mitchell PK, Klein NP, et al. Protection of 2 and 3 mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19 – VISION Network, August 2021 – March 2022. Journal of Infectious Diseases. Advance online publication. https://doi.org/10.1093/infdis/jiac458
  • Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated — VISION Network, 10 states, December 2021–June 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(29):925-933. https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e1.htm?s_cid=mm7129e1_w
  • Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19–associated emergency department and urgent care encounters and hospitalizations among non-immunocompromised children and adolescents aged 5–17 years — VISION Network, 10 states, April 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(9):352-358. https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w
  • Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION Network, 10 states, August 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(7):255-263. https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm?s_cid=mm7107e2_w
  • Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION network, 10 states, August 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(4):139-145. https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w
  • Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults — VISION Network, 10 states, December 2021–March 2022. MMWR. Morbidity and Mortality Weekly Report. 2022;71(13):495-502. https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e2.htm?s_cid=mm7113e2_w
  • Bozio CH, Butterfield K, Irving SA, et al. Relative Risks of COVID-19-Associated Hospitalizations and Clinical Outcomes by Age and Race/Ethnicity-March 2020-March 2021. Open Forum Infectious Diseases. 2022;9(10):ofac376. doi:https://doi.org/10.1093/ofid/ofac376

2021

  • Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults — Nine states, January–September 2021. MMWR. Morbidity and Mortality Weekly Report. 2021;70(44):1553-1559. https://www.cdc.gov/mmwr/volumes/70/wr/mm7044e3.htm?s_cid=mm7044e3_w
  • Grannis SJ, Rowley EA, Ong TC, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19–associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance — Nine states, June–August 2021. MMWR. Morbidity and Mortality Weekly Report. 2021;70(37):1270-1273. https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm
  • Thompson M, Stenehjem E, Grannis SJ, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. New England Journal of Medicine. 2021; 385(15): 1355-1371. https://doi.org/10.1056/NEJMoa2110362
  • Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021. MMWR Morbidity and Mortality Weekly Report. 2021;70(44). doi:https://doi.org/10.15585/mmwr.mm7044e1

Resources

Print
Content Source:
National Center for Immunization and Respiratory Diseases (NCIRD)